Skip to content

Long-term Impact of NMDAR Encephalitis

Social and Psychological Long-term Impact of NMDA Receptor Encephalitis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06609044
Acronym
SAPIENCE2
Enrollment
20
Registered
2024-09-23
Start date
2024-12-16
Completion date
2025-04-04
Last updated
2025-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Encephalitis

Keywords

NMDAR encephalitis, psychosocial impact

Brief summary

NMDA receptor antibody encephalitis is a rare autoimmune neurological disease of the central nervous system with an estimated incidence of 1.5 people per million per year. Patients with anti-NMDAR encephalitis experience an acute phase of the disease characterized by psychosis, memory loss, seizures, autonomic nervous system instability, or coma. Since the discovery of this disease 14 years ago by Prof. Dalmau, the clinical presentation of the acute phase has been well characterized, while the psychosocial impact of the disease remains largely unexplored. Currently, there are few cohort studies of patients that have identified persistent cognitive impairment as a factor impacting remission after the acute phase. Given the scarcity of information concerning the post-acute phase, it is therefore essential to determine the long-term social and psychological outcomes and their daily effects on the social and functional life of this severe disease. This is especially important as the patients are young, with a median age of 21 years, and may face lasting limitations potentially detrimental to their success in professional, educational, or social environments.

Detailed description

This study will help improve the management of patients with anti-NMDAR encephalitis : * By providing the first assessment of long-term cognitive, psychological and social consequences * By characterizing the patient's journey through the disease * By developing a standardized neuropsychological assessment which will improve the assessment of the patient in the post-acute phase As well as improving patient care in the long term through the drafting of specific medical recommendations.

Interventions

None listed

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients with NMDAR encephalitis * Age ≥ 18 years old * Patient affiliated to a social security system * No opposition from the patient

Exclusion criteria

* Patients whithout NMDAR encephalitis * Age < 18 years old * Patient under guardianship or curatorship * Patient with neurological disorders pre-existing encephalitis

Design outcomes

Primary

MeasureTime frameDescription
Psychosocial questionnaires of patients with anti-NMDAR encephalitis after the acute phase of the disease.50 MINUTESNeuropsychological Questionnaires : * RAVLT questionnaire (no score) * EMPAN questionnaire (no score)
Analysis of cognitive assessments of patients with anti-NMDAR encephalitis after the acute phase of the disease.40 MINUTESScore of PROMs questionnaires : * FSS (score : /63) * HADS (score : /42) * EQ5D5L (score : /100) * BDI-II (no score ) * MMQ (no score) * PSQI (no score)
Patient's experience of the disease1 YearScore of Clinical questionnaire about patient's experience of the disease

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026